A5035122536- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Esophageal and GI Pathology
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Advances in Oncology and Radiotherapy
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Health Systems, Economic Evaluations, Quality of Life
- Radiopharmaceutical Chemistry and Applications
- Melanoma and MAPK Pathways
- Radiation Therapy and Dosimetry
- Intraperitoneal and Appendiceal Malignancies
- CAR-T cell therapy research
Singleton Hospital
2015-2024
Swansea University
2019-2024
Swansea Bay University Health Board
2015-2024
Velindre Cancer Centre
2008-2020
Mount Vernon Hospital
2019
Beatson West of Scotland Cancer Centre
2016-2018
Cardiff University
2014-2017
University of Wales Institute Cardiff
2015-2017
Institute of Infection and Immunity
2017
Oxford BioMedica (United Kingdom)
2017
Abstract Purpose: Anticancer T-cell responses can control tumors, but immunosuppressive mechanisms in vivo prevent their function. The role of regulatory T cells (Tregs) metastatic colorectal cancer is unclear. We have previously shown depletion Tregs enhances cancer–specific effector responses. Low-dose cyclophosphamide targets animal models and some human studies; however, the effect unknown. Experimental Design: Fifty-five patients with were enrolled a phase I/II trial randomly assigned...
The success of immunotherapy with checkpoint inhibitors is not replicated in most cases colorectal cancer; therefore, different strategies are urgently required. oncofetal antigen 5T4 expressed more than 90% metastatic cancer (mCRC). Preliminary data using modified vaccinia Ankara-5T4 (MVA-5T4) mCRC demonstrated that it safely induced serologic and T-cell responses.
Pelvic exenteration is a potentially curative treatment for locally advanced primary rectal cancer. Previous studies have been limited by small sample sizes and heterogeneous data. A consecutive series of patients was studied to identify the clinicopathological determinants survival.All undergoing pelvic exenterative surgery cancer (1992-2014) at this hospital were analysed. The outcome measure 5-year overall survival. Secondary endpoints included length stay, complication rate, 30-day...
Abstract Background This study compared outcomes after surgery alone for stage II/ III rectal cancer in a tertiary unit versus highly selective use of preoperative chemoradiotherapy (CRT). Methods was single-centre retrospective cohort consecutive patients receiving potentially curative II and primary cancer. CRT given only magnetic resonance imaging-predicted circumferential resection margin (CRM) involvement nodal disease (at least N2). Primary endpoints were CRM local recurrence rates....
Oxaliplatin-capecitabine (OxCap) and carboplatin-paclitaxel (CarPac) based neo-adjuvant chemoradiotherapy (nCRT) have shown promising activity in localised, resectable oesophageal cancer.
Both oxaliplatin/capecitabine-based chemoradiation (OXCAP-RT) and carboplatin-paclitaxel based radiation (CarPac-RT) are active regimens in oesophageal adenocarcinoma, but no randomised study has compared their efficacy toxicity. This phase II “pick a winner” trial will identify the optimum regimen to take forward future III against neo-adjuvant chemotherapy, current standard UK. Patients with resectable adenocarcinoma of oesophagus or Siewert Type 1–2 gastro-oesophageal junction (GOJ), ≥T3...